Belgian neurotechnology business ReVision Implant has closed an oversubscribed €4 million funding round, in a deal that pushes one of Europe’s most ambitious brain-interface ventures out of the laboratory and into the early stages of clinical work.

The raise, drawn entirely from private investors, attracted both existing backers and a fresh cohort of European business leaders and medtech operators, an investor mix that tends to signal more than passing enthusiasm in a sector where capital has lately been notoriously hard to lock in. It also follows a run of public support that includes a clutch of competitive European Innovation Council grants, among them the €2.4 million FlairVision project, alongside backing from the Plug & Play and imec.istart incubators.

For a deep-tech business of this stage, the combination of dilutive private money and non-dilutive EIC support is precisely the funding stack British and European life-sciences founders have spent the past 18 months arguing the UK still cannot easily replicate, a point this magazine has explored in its coverage of the UK’s £850m Cambridge life-sciences deal.

Bypassing the eye altogether

ReVision Implant is developing a cortical visual prosthesis intended to restore functional vision in people with severe blindness, including the substantial cohort of patients whom retinal or optic-nerve therapies cannot help. Rather than attempting to repair the eye, the device interfaces directly with the brain’s visual cortex, sidestepping damage further down the visual pathway and, in principle, allowing recipients to perceive and interpret visual information generated by an external camera.

It is the sort of high-bandwidth, brain-machine interface work that has, until recently, been treated as the preserve of a handful of headline-grabbing American firms. Yet the science has moved on quickly, and a small number of European challengers, ReVision Implant among them, are now closing the gap on conditions ranging from quadriplegia and locked-in syndrome to aphasia, amputation and blindness.

In-house manufacturing as a strategic moat

Three months ago the company began standing up its own cleanroom facilities, a deliberate move to bring critical manufacturing steps in-house ahead of clinical trials. For a Class III implantable device, control over production is not a back-office detail; it is a regulatory and commercial moat. Outsourcing every step tends to slow iteration, raise costs and complicate audits, problems that have hobbled more than one European medtech hopeful at exactly the wrong moment.

Frederik Ceyssens, chief executive of ReVision Implant, said the round marked the point at which the business pivots from pure development to operational scale-up. “We are investing in our own cleanroom environment to bring important manufacturing steps in-house, while expanding our team and advancing our regulatory compliance and clinical programme over the coming years,” he said. “At the same time, we are continuing product development and strengthening our collaborations with other medtech companies as we move closer to bringing our technology to patients.”

Breakthrough designation and a Q3 2026 trial

The funding lands shortly after the U.S. Food and Drug Administration awarded the company Breakthrough Device designation, a status reserved for technologies addressing serious or irreversibly debilitating conditions, and one that opens up earlier and more frequent engagement with FDA reviewers. With the first phase of its first-in-human study already cleared by regulators and pencilled in for the third quarter of 2026, ReVision Implant has the rare luxury of moving into a known clinical window with cash in the bank.

For investors looking at neurotechnology at large, the read-across is unmistakable. The success of recent rounds elsewhere, such as the £8m British Business Bank-backed investment in NRG Therapeutics, suggests appetite for serious science is returning, even as headline venture funding remains patchy. If ReVision Implant’s first patients see anything at all later this year, the company will find itself at the centre of a market that, on conservative estimates, could one day help millions.

Read more:
Revision Implant lands oversubscribed €4m round to take brain-powered sight implant into the clinic